Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Stalls Generic Lipitor With Ranbaxy Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Settlement could give 20 more months of unchallenged U.S. marketing.

You may also be interested in...



As Launch Date Nears, Is Ranbaxy Exploring Talks To Monetize Lipitor First-launch Opportunity With Generic Rivals?

Agreement with Impax on launch of generic tamsulosin could be one model for atorvastatin strategy.

As Launch Date Nears, Is Ranbaxy Exploring Talks To Monetize Lipitor First-launch Opportunity With Generic Rivals?

Agreement with Impax on launch of generic tamsulosin could be one model for atorvastatin strategy.

As Launch Date Nears, Is Ranbaxy Exploring Talks To Monetize Lipitor First-launch Opportunity With Generic Rivals?

MUMBAI - As Ranbaxy struggles to deal with U.S. FDA allegations of GMP violations and data falsification at its two Indian manufacturing sites - Paonta Sahib and Dewas - clouds are gathering over its ability to launch a generic equivalent of the planet's largest drug brand Lipitor (atorvastatin) in the United States, about a year from now

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067932

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel